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Abstract
 
Aspirin therapy inhibits prostaglandin biosynthesis without directly acting on lipoxygenases, yet
via acetylation of cyclooxygenase 2 (COX-2) it leads to bioactive lipoxins (LXs) epimeric at car-
bon 15 (15-epi-LX, also termed aspirin-triggered LX [ATL]). Here, we report that inflamma-
 
tory exudates from mice treated with 
 
v
 
-3 polyunsaturated fatty acid and aspirin (ASA) generate
a novel array of bioactive lipid signals. Human endothelial cells with upregulated COX-2
 
treated with ASA converted C20:5 
 
v
 
-3 to 18
 
R
 
-hydroxyeicosapentaenoic acid (HEPE) and
15
 
R
 
-HEPE. Each was used by polymorphonuclear leukocytes to generate separate classes of
 
novel trihydroxy-containing mediators, including 5-series 15
 
R
 
-LX
 
5
 
 and 5,12,18
 
R
 
-triHEPE.
These new compounds proved to be potent inhibitors of human polymorphonuclear leukocyte
transendothelial migration and infiltration in vivo (ATL analogue 
 
. 
 
5,12,18
 
R
 
-triHEPE 
 
. 
 
18
 
R
 
-
HEPE). Acetaminophen and indomethacin also permitted 18
 
R
 
-HEPE and 15
 
R
 
-HEPE genera-
tion with recombinant COX-2 as well as 
 
v
 
-5 and 
 
v
 
-9 oxygenations of other fatty acids that act
on hematologic cells. These findings establish new transcellular routes for producing arrays of
bioactive lipid mediators via COX-2–nonsteroidal antiinflammatory drug–dependent oxygen-
ations and cell–cell interactions that impact microinflammation. The generation of these and re-
lated compounds provides a novel mechanism(s) for the therapeutic benefits of 
 
v
 
-3 dietary sup-
plementation, which may be important in inflammation, neoplasia, and vascular diseases.
Key words: dietary PUFA • eicosanoids • leukocytes • cardiovascular disease
 
Introduction
 
Numerous reports of the past 25 years suggest that supple-
mentation of dietary omega-3 polyunsaturated fatty acids
(
 
v
 
-3 PUFA) with linseed, canola, or fish oils has beneficial
effects in human diseases and laboratory animals (for review
see references 1 and 2). These have included lively discus-
sions of potential antithrombotic, immunoregulatory, and
antiinflammatory responses relevant in arteriosclerosis, ar-
thritis, and asthma (1) as well as antitumor and antimeta-
static effects (3). Their potential for preventative actions in
cardiovascular diseases was recently bolstered with the find-
ing that major dietary 
 
v
 
-3 PUFAs, eicosapentaenoic acid
(C20:5 
 
v
 
-3; EPA) and docosahexaenoic acid (C22:6 
 
v
 
-3;
DHA), have a dramatic effect on ischemia-induced ventric-
ular fibrillation and can protect against sudden cardiac death
in dogs (4). Emergence of such possible preventative and/
or therapeutic actions of 
 
v
 
-3 PUFA supplementation in in-
fant nutrition, cardiovascular diseases, and mental health
has led to a call for recommended dietary intakes by an in-
ternational workshop (5). Also, the Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto Miocardico-Pre-
venzione trial evaluated the effects of 
 
v
 
-3 PUFA supple-
mentation with 
 
.
 
11,300 patients surviving myocardial in-
farction taking 
 
z
 
1 g of 
 
v
 
-3 PUFA daily (
 
n
 
 5 
 
2,836) along
with recommended preventive treatments including aspi-
rin, and reported a significant benefit with a decrease in
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cardiovascular death (6). However, the cellular and molec-
ular mechanism(s) for dietary 
 
v
 
-3 protective actions in all
of the studies to date remain largely unexplained.
It is believed that the actions of the major lipid of fish oil,
C20:5, are based upon (a) preventing conversion of ara-
chidonic acid (C20:4 
 
v
 
-6; AA) to proinflammatory ei-
cosanoids (i.e., prostaglandins [PGs] and leukotrienes
[LTs]); (b) serving as an alternate substrate producing 5-se-
ries LTs that are less potent; and/or (c) conversion by cy-
clooxygenase (COX) to 3-series prostanoids (i.e., PGI
 
3
 
)
with potencies equivalent to their 4-series PG counterparts
to maintain antithrombotic actions (1, 3, 4). These and
other explanations offered (1–5) have not been generally
accepted because of the lack of molecular evidence in vivo
and the high concentrations of 
 
v
 
-3 PUFA required to
achieve putative “beneficial actions” in vitro.
Although the proinflammatory roles of LT and PG are
well appreciated (7, 8), there is new evidence that other
eicosanoids derived from arachidonate, namely lipoxins
(LXs) and their endogenous analogues, the aspirin-trig-
gered 15 epimer LXs (ATLs), are potent counterregulators
of PMN-mediated injury and acute inflammation (9–11).
At least two isoforms for COX, the classic site of action for
nonsteroidal antiinflammatory drugs (NSAIDs), have been
uncovered (COX-1 and 2) that appear to serve separate
physiologic and pathophysiologic roles in humans (12).
Each COX isoform carries dual enzymatic activities, a
 
bis
 
oxygenase and a peroxidase. Inhibition of COX-2 is the
current focus of several pharmaceutical companies, as selec-
tive inhibition of COX–2 without blocking COX-1 could
reduce unwanted side effects associated with traditional
NSAIDs (13). In this regard, acetylation of COX-2 by the
classic NSAID, aspirin (ASA), prevents the formation of
prostanoids (12), but the acetylated enzyme remains active
in situ to generate 15
 
R
 
-hydroxyeicosatetraenoic acid (15
 
R
 
-
HETE) from C20:4 (14, 15) that is released and converted
by activated inflammatory cells to the 15-epimeric LXs.
Synthetic analogues of these natural local mediators with
prolonged biological half-life display potent antiinflamma-
tory properties (11, 16), providing evidence that cell–cell
interactions can be responsible for conversion of AA to
mediators that possess antiinflammatory properties.
Oxidation of C20:4 via P450 in endothelial cells (ECs)
may also lead to 11,12-epoxyeicosatetraenoic acid that ap-
pears to block EC activation (17), while nonenzymatic ox-
idation of EPA can downregulate EC adhesion molecules
(18). As PMN–vessel interactions are pivotal to recruitment
and PMN-dependent tissue injury, the local signals in-
volved in their “cross-talk dialogue” are of interest. Our
finding that aspirin-acetylated COX-2 remains active in
vivo (14) to generate specific ATLs that can be effectors of
well established antiinflammatory reactions offers a mecha-
nism for beneficial effects of ASA that cannot be attributed
to inhibition of prostanoids alone (8, 12). New therapeutic
applications for ASA and related NSAIDs continue to
emerge. However, they usually require molecular defini-
tion to provide a rationale. This includes the reported pro-
phylactic benefit of ASA in colorectal cancer and the lower
 
risk of a second myocardial infarction (for review see refer-
ence 19). In view of the qualitatively overlapping beneficial
profiles assigned to dietary 
 
v
 
-3 PUFA in human disease
(1–6), we sought evidence for novel pathways for lipid-
derived signals that could possibly provide a molecular basis
and also serve as markers for these beneficial actions.
 
Materials and Methods
 
Zymosan, hematin, NADPH, and ASA were from Sigma-
Aldrich. EPA (Cayman Chemical) and other synthetic standards,
hydroxy fatty acids, and intermediates used for identification were
purchased from Cascade Biochem Ltd.
 
 Bacillus megaterium 
 
was
from American Type Culture Collection. Materials used in liquid
chromatography tandem mass spectrometry (LC/MS/MS) analy-
ses were from vendors given in reference 20.
Human PMNs were freshly isolated from venous blood of
healthy volunteers (that declined taking medication for 2 wk be-
fore donation; Brigham and Women’s Hospital protocol no. 88-
02642) by Ficoll gradient and enumerated. Human umbilical vein
or microvascular ECs (HUVECs or HMVECs, respectively) were
cultured for transendothelial migration (10). HMVEC monolay-
ers (one, two, or three passages) were seeded (
 
z
 
2 
 
3
 
 10
 
5
 
 cells/
cm
 
2
 
) on polycarbonate permeable supports precoated with 0.1%
gelatin for incubations with NSAIDs and PUFA.
Inflammatory exudates were initiated with intrapouch injec-
tion of TNF-
 
a
 
 (R&D Systems) into 6 d dorsal air pouches (16)
with 6–8-wk-old male FVB mice (fed standard rodent diet 5001
containing 0.26% n-3 fatty acids) followed by ASA (500 
 
m
 
g) at
3.5 h and 300 
 
m
 
g C20:5/pouch at 4 h. At 6 h, pouches were lav-
aged (3 ml saline), and exudate cells were enumerated and acti-
vated (4 
 
m
 
M A
 
23187
 
, 37
 
8
 
C, 20 min). Inhibition of TNF-
 
a
 
–stimu-
lated (100 ng/pouch, FVB strain) PMN infiltration with
intravenous tail injection of either 18
 
R
 
-hydroxyeicosapentaenoic
acid (HEPE), 5,12,18
 
R
 
-HEPE, or 15-epi-LXA
 
4
 
 analogue was
determined (16) with pouch lavages taken at 4 h.
Specific [
 
3
 
H]LTB
 
4
 
 (NEN Life Science Products) binding was
performed with human embryonic kidney (HEK)293 cells stably
transfected with human LTB
 
4
 
 receptor (11). Human recombinant
COX-2 (a gift from Dr. R.A. Copeland, DuPont Merck, Wil-
mington, DE) was overexpressed in 
 
Sf
 
9 insect cells (American Type
Culture Collection) with microsomal fractions (
 
z
 
8 
 
m
 
l) suspended
in Tris (100 mM, pH 8.0) as in reference 21. NSAIDs were incu-
bated (i.e., ASA, 
 
z
 
1 mM) at 37
 
8
 
C for 30 min before addition of
PUFA (20 
 
m
 
M), and conversions were also monitored using
1-
 
14
 
C–labeled C20:4 or C20:5 (NEN Life Science Products). 
 
B
 
.
 
megaterium
 
 was grown in Bacto Nutrient Broth (Fisher Scientific)
at 30
 
8
 
C with shaking. To prepare standards for 18
 
R
 
-HEPE, a
biogenic synthesis was used with 
 
B
 
.
 
 megaterium
 
 sonicates incu-
bated with NADPH (2 mM) and C20:5 (330 
 
m
 
M) in 2 M Tris
buffer, pH 8.1. Similar conditions were employed to convert
LTB
 
5
 
 (15 
 
m
 
M) to novel products; see Results. Incubations were
extracted (9) with deuterium-labeled internal standards (15-
HETE and C20:4) for LC/MS/MS analysis (14, 16) using a
Finnigan LCQ equipped with a LUNA C18-2 (150 
 
3 
 
2 mm; 5
 
m
 
M) column and a rapid spectra scanning UV/Vis detector. Also,
a Chiralcel OB-H column (J.T. Baker) was used to determine 
 
R
 
and 
 
S
 
 alcohol configurations of monohydroxy-PUFA using iso-
cratic (hexane/isopropanol 96:4 vol/vol). Detailed procedures for
isolation, quantitation, and structural determination of lipid-derived
mediators were recently reported (20) and used here essentially as
described for the elucidation of the novel products. 
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Results and Discussion
 
Because ASA triggers formation of epimeric forms of nat-
urally occurring bioactive eicosanoids (9), we tested the
concept that NSAIDs might promote the formation of
novel mediators from 
 
v
 
-3 PUFAs. Inflammatory exudates
formed in murine air pouches via intrapouch injections of
TNF-
 
a
 
 with 
 
v
 
-3 and ASA on board (2 h) generated several
novel compounds (Fig. 1). These mice were fed a standard
rodent diet containing 0.26% 
 
v
 
-3 PUFA. LC/MS/MS
analyses of the exudate-derived materials demonstrated
monohydroxy acids, depicted in selected ion chromato-
grams from acquired results recalled at m/z 317 (Fig. 1 A),
i.e., 18-hydroxy-EPA (18-HEPE) and 5-HEPE, which co-
eluted with synthetic 5
 
S
 
-HEPE as well as novel trihydroxy-
containing compounds derived from C20:5. LC retention
times and MS/MS spectra (Fig. 1, B and C) gave product
ions consistent with structures shown in the respective in-
sets, namely m/z 317 
 
5 
 
[M-H]
 
2
 
, 299 
 
5 
 
[M-H]
 
2
 
–H
 
2
 
O,
273 
 
5 
 
[M-H]
 
2
 
–CO
 
2
 
, 255 
 
5 
 
[M-H]
 
2
 
–H
 
2
 
O,–CO
 
2
 
. Diag-
nostic ions consistent with 18-HEPE identification were
present at m/z 259 (Fig. 1 B) and 5-HEPE at m/z 115 (Fig.
1 C). These criteria were used throughout for identifica-
tion. The stereochemistry of the alcohol at carbon 18 was
established for exudate-derived 18-HEPE using a chiral col-
umn, and a reference 18
 
R
 
-HEPE was prepared via biogenic
synthesis using 
 
B
 
.
 
 megaterium
 
 (see Materials and Methods).
This microbe monooxygenates fatty acids and, for example,
converts C20:4 to 18
 
R
 
-HETE (22, 23). The alcohol con-
figuration at position 18 proved to be 
 
.
 
98% 
 
R
 
. These find-
ings indicated that murine inflammatory exudates exposed
in vivo to C20:5, 
 
v
 
-3 and ASA produced 5-lipoxygenase
pathway 5-series 5
 
S
 
-HEPE, a product also identified with
human PMNs (24), as well as a novel 18
 
R
 
-HEPE, whose
route of formation was determined (vide infra). Air pouch
inflammatory exudate cells from these ASA- and EPA-
treated mice contained predominantly PMN (as in Fig. 1),
which were 25–60% lower in number than in exudates
formed with TNF-
 
a
 
 alone (
 
n
 
 5 
 
3). Also, these exudates,
when activated with ionophore A
 
23187
 
 (4 
 
m
 
M), generated
essentially equivalent amounts of 18
 
R
 
-HEPE (10.2 
 
6
 
 4.3
ng/10
 
6
 
 cells) and 5
 
S-HEPE (10.9 6 2.9 ng/106 cells).
Evidence for novel trihydroxy-containing products was
also obtained in these inflammatory exudates (Fig. 1 D).
Figure 1. Inflammatory exudates
from murine dorsal pouches treated
with aspirin generate novel com-
pounds: LC/MS/MS. TNF-a–
induced leukocyte exudates col-
lected at 6 h from FVB mice given
ASA (3.5 h at 500 mg/air pouch)
and EPA (4 h at 300 mg/pouch)
contained (2.3 6 0.5 3 106 leuko-
cytes per pouch); see Materials and
Methods. (A) Selected ion chro-
matogram of mono-HEPEs. (B)
MS/MS of 18R-HEPE. (C) MS/MS
of 5S-HEPE. (D) MS/MS of
12,15,18R-triHEPE (see text for
identification of diagnostic ions).
Results are representative of n 5 4.1200 Endogenous Antiinflammatory Lipid Mediator Arrays
Ions present within MS/MS were consistent with a trihy-
droxy-containing product from C20:5 with a parent ion at
m/z 349 5 [M-H]2 and product ions of structural signifi-
cance present at m/z 291 and 195 that are consistent with
fragmentations denoted in the inset (Fig. 1 D). Also, an ob-
served 270 nm UV absorbance maximum, indicative of a
conjugated triene, together with the presence of the m/z 5
291 (cleavage C17–C18 positions) as well as the 20-carbon
structure, implicated that 18R-HEPE and the triHEPE
were biosynthetically related.
It was of interest to determine whether these new com-
pounds were also generated by human cells and if they
possess bioactivities. To this end, human ECs known to
induce COX-2 with IL-1b (9) or hypoxia (not shown)
were pulsed with EPA and treated with ASA, and ex-
tracted materials were subject to LC/MS/MS analysis (Fig.
2 A). Selected ion monitoring at m/z 259 revealed that
HUVECs treated with ASA converted EPA to 18R-HEPE
(Fig. 2 A). Also, HMVECs treated with ASA and EPA
generated 18-HEPE (10.6 ng/106 cells) and 15-HEPE (6.0
ng/106 cells) (n 5 2, four determinations; data not shown).
These observations implicated the involvement of COX-2
in the generation of these compounds, which proved to be
the case with recombinant human COX-2 exposure to
ASA and v-3 PUFA (Table I), findings that may be of
clinical significance.
As shown in Table I, linoleic acid (C18:2) was con-
verted to both 13-hydroxy-9Z,11E-octadecadienoic acid
(13-HODE;  v-5 oxygenation) and 9-HODE (v-9),
which were greatly diminished by ASA but not completely
abolished. AA was converted to 15R-HETE (v-5) as well
as 11R-HETE (v-9), consistent with earlier findings (9).
ASA triggered the appearance of a lipoxygenase activity
that switched to 15R-HETE production by acetylated
COX-2 (9, 14, 15), which did not appear to influence
11R-HETE formation (Table I). 11R-HEPE was the ma-
jor product with EPA and COX-2, with lesser amounts of
15R-HEPE (v-5) and 18R-HEPE (v-2). 1-14C–labeled
EPA was used to confirm precursor–product relationships
(n 5 3). ASA acetylation of COX-2 led to an approxi-
mately twofold increase in 18R-HEPE (v-2), with a
.85% reduction in 11R-HEPE (the ratio of positional ox-
ygenations with C20:5 was 1:1:0.3, with 18R < 15R .
11R). Hence, together they suggested that acetylated
COX-2 in ECs (Fig. 2) was a dominant source of 18R-
HEPE and 15R-HEPE.
Interestingly and unlike the isolated COX-2 product
profiles, neither 11R-HEPE (from C20:5) nor 11R-HETE
(from C20:4) were major products of the vascular ECs (Ta-
ble I and Fig. 2). With the selective COX-2 inhibitor
NS398 (12, 13), these oxygenations were reduced, and
only 18R-HEPE formation from EPA appeared to escape
inhibition (Table I). These results suggest that ASA treat-
ment at local sites of inflammation along with v-3 PUFA
Figure 2. Human ECs and PMNs: novel trihydroxy-containing compounds LC/MS/MS. (A) HUVECs treated with IL-1b (24 h) and ASA. (B) Hu-
man PMNs (z 30 3 106/ml) incubated (30 min, 378C) with serum-treated zymosan (100 ng/ml) and acetylated ASA-recombinant COX-2–derived
products from EPA. (C) MS/MS of 5,12,18R-triHEPE (see text for ions and fragmentation). (D) MS/MS of 15-epi-LXA5. Results are representative of
n 5 3–5 for PMNs and n 5 3 for ECs.1201 Serhan et al. Brief Definitive Report
(i.e., EPA; C20:5, v-3) administration, as exemplified by
cytokine-driven acute inflammation (Fig. 1), can convert
EPA via COX-2 to 18R-HEPE and 15R-HEPE.
Because human PMNs convert ASA-triggered, COX-
2–derived 15R-HETE to 15-epi-LXA4 (9) and EPA is
converted to 5-series LX by human leukocytes (25) as well
as trout macrophages (26), we next evaluated whether acti-
vated human PMNs engaged in phagocytosis handle acety-
lated COX-2–derived C20:5, v-3 products 18R-HEPE
and 15R-HEPE. Serum-treated zymosan, a phagocytic
stimulus, initiated the utilization and conversion of acety-
lated COX-2 C20:5-derived products to two classes of tri-
hydroxy-containing EPE, determined again by selected ion
monitoring at m/z 349.5 [M-H]2, the base peak molecular
ion for these products (Fig. 2 B). One, shown in Fig. 2 C,
gave essentially the same MS/MS observed in Fig. 1 D
from murine cells and was consistent with the 5,12,18R-
triHEPE structure depicted in the inset giving diagnostic
ions (Fig. 2 C) at m/z 305, 233, 195, and 291 (Fig. 1 D).
This product is an 18R-hydroxy–carrying “LTB5-like”
structure (see Fig. 2 D, inset). Indeed, when isolated 18R-
HEPE was incubated as above with activated PMNs, it was
converted to several compounds, including this product.
Also, synthetic LTB5 incubated with B. megaterium homog-
enates and NADPH at pH 8.0 to facilitate hydroxylations
(23) was transformed to a trihydroxy product (n 5 3) with
an m/z 291 ion characteristic for the presence of the 18R
alcohol group as obtained from human PMNs shown in
Fig. 2 C. These independent lines of evidence indicated
that PMNs take up 18R-HEPE, which is converted by
their 5-lipoxygenase, to insert molecular oxygen and in
subsequent steps to 5-hydro(peroxy)-18R-DiH(p)EPE and
5(6)epoxide formation to 5,12,18R-triHEPE (an 18R-car-
rying LTB5-like product) that is likely to possess the ste-
reochemistry of LTB5 (24), retaining the 18R chirality of
the precursor.
In an analogous biosynthetic fashion, 15R-HEPE was
converted by PMN via 5-lipoxygenation to a 5-series
LXA5 analogue (Fig. 2 D) that also retains their C15 con-
figuration. Its MS/MS gave prominent ions, m/z 305, 233,
and 251, depicted in the MS/MS spectrum, namely 15-epi-
LXA5, consistent with 15S-containing LX5 structures (5-
series) observed from endogenous sources of EPA in trout
macrophages (26). In this case, the chirality of the precursor
15R is retained by human PMN to give 15-epi-LXA5 (Fig.
2 D), which is the 5-series v-3 analogue of 15-epi-LXA4.
As with LX biosynthesis, conversion of both 18R- and
15R-HEPE by activated PMNs with 5-lipoxygenation was
accompanied with a reduction in LTB4 formation (not
shown). Together, these results indicate that isolated hu-
man ECs and PMNs (Fig. 2) can generate the novel prod-
ucts observed with inflammatory exudates (Fig. 1).
Transendothelial migration is a pivotal event in PMN
recruitment and inflammation and a recognized locus of
action for traditional antiinflammatory therapies (27). En-
dogenous lipid mediators that can control these cell–cell in-
teractions are of interest. Therefore, we isolated and as-
sessed 5,12,18R-triHEPE and its precursor 18R-HEPE on
human PMN transmigration. Both compounds inhibited
LTB4-stimulated PMN transendothelial migration (Fig. 3
A) with an apparent IC50 of 5–50 nM for 5,12,18R-tri-
HEPE and IC50 .1.0 mM for 18R-HEPE. Thus, the new
5-series members, namely, 18R-carrying trihydroxy-HEPE
and 18R-HEPE, inhibited PMN migration, as did 15-epi-
Table I. Hydroxy Compounds Generated from PUFA and Recombinant Human COX-2 with ASA or a Selective COX-2 Inhibitor
Hydroxy-containing compounds
(ng/incubation)
PUFA NSAID v-2 v-5 v-9
13-HODE 9-HODE
C18:2 ASA – 2.9 6 0.6 25.2 6 17.8
C18:2 Vehicle alone – 55.0 6 18.7 243.0 6 68.6
15R-HETE 11R-HETE
C20:4 ASA – 234.0 6 112.5 1.4 6 1.6
C20:4 Vehicle alone – 11.5 6 8.2 1.8 6 1.0
C20:4 Selective inhibitor – 5.5 6 0.8 0.9 6 0.1
18R-HEPE 15R-HEPE 11R-HEPE
C20:5 ASA 16.2 6 3.3 16.8 6 5.8 5.4 6 3.3
C20:5 Vehicle alone 7.0 6 3.3 17.9 6 5.2 40.7 6 10.3
C20:5 Selective inhibitor 5.8 6 2.6 0.0 6 0.6 0.0 6 0.3
Results are the mean 6 SEM, n = 3. The selective COX-2 inhibitor NS398 was used at 100 mM. All products were extracted, identified, and
quantitated using internal standards and LC/MS/MS. Compounds of interest are shown in bold type.1202 Endogenous Antiinflammatory Lipid Mediator Arrays
LXA4 and its omega end analogue (10, 16), tested in paral-
lel for direct comparison (Fig. 3 A). Their rank order of
potency was 15-epi-LXA4 stable analogue . 5,12,18R-tri-
HEPE . 18R-HEPE.
The G protein–coupled receptor for LTB4 was identified
(28), and to determine whether these 18R-containing
products interact with the human LTB4 receptors to block
PMNs, this receptor was cloned (11) from reported se-
quences (28) and stably expressed in HEK293 cells for
competition binding experiments (Fig. 3 B). The homoli-
gand LTB4 effectively competed (IC50 < 2.5 nM). 18R-
HEPE did not, while both LTB5 and 5,12,18R-triHEPE
competed (IC50 z0.5 mM), giving a trend with LTB5 .
5,12,18R-triHEPE. Although the 5,12,18R-triHEPE and a
related structure (i.e., LTB5) were substantially less effective
than 4-series LTB4, consistent with the reduced PMN ac-
Figure 3. The novel compounds inhibit human PMN transmigration and inflammation in the murine air pouch. (A) Inhibition of PMN transendo-
thelial migration. PMNs were incubated with isolated compounds [10210–1026 M] 18R-HEPE (s), 5,12,18R-triHEPE (d), or ATL analogue used for
reference (r), and transmigration was initiated using an optimal amount of LTB4 [10 nM] (100%) and HUVEC coincubations (90 min, 378C). Results
are the mean 6 SEM; n 5 3. (B) Competition binding with human recombinant LTB4 receptor. LTB4 receptor stably expressed in HEK293 cells (z5 3
105 cells/incubation) were incubated with [3H]LTB4 (z1 nM) plus LTB4 (j) and 18R-HEPE (s), 5,12,18R-triHEPE (d), or LTB5 (u). Results are the
mean 6 SEM from n 5 3. (C) Inhibition of leukocyte trafficking in 6 d dorsal air pouch. TNF-a (100 ng) was injected intrapouch and 100 ng i.v. tail
vein of test compound. ATLa (analogue 15(S)-16(parafluoro)-phenoxy-LXA4; reference 16) was used for comparison. Results represent n 5 4.
Figure 4. Proposed scheme for generating functional arrays of lipid signals from v-3 PUFA via transcellular processing: endogenous inhibitors of mi-
croinflammation. At sites where COX-2 is upregulated and treated with NSAIDs, PG formation from C20:4 is blocked. Systemic v-3 PUFAs are con-
verted via a COX-2–NSAID lipoxygenase–type mechanism that abstracts hydrogen in a stereospecific fashion at C16 or C13 in C20:5 to give R inser-
tions of molecular O2 to yield 15R-H(p)EPE or 18R-H(p)EPE to form epoxides or are reduced to alcohols. The complete stereochemistry for each of
the trihydroxy compounds remains to be determined, and the compounds are depicted in their likely configurations. These compounds interact with
cells in the local microenvironment, inhibiting PMN recruitment. COX-2–NSAID-dependent hydrogen abstraction and insertion of molecular oxygen
occurs with all v-3 PUFAs containing 1,4-cis pentadiene units tested (see text for details). Thus, sequential oxygenations of v-3 PUFA during cell–cell
interactions generate novel arrays of signals of interest in microinflammation.1203 Serhan et al. Brief Definitive Report
tivity of LTB5 (24), their potency for displacing [3H]LTB4
was in the range of currently available synthetic LTB4 re-
ceptor antagonists (not shown). These findings suggest that
5,12,18R-triHEPE might serve as a damper for LT-medi-
ated responses in vivo if generated in appropriate quantities
within the microenvironment as well as a biotemplate for
total synthesis of new classes of receptor antagonists. When
administered intravenously into tail at low levels (100 ng),
5,12,18R-triHEPE was a potent inhibitor of PMN infiltra-
tion into murine dorsal air pouches (Fig. 3 C), as was a 15-
epi-LX stable analogue (16) given at equivalent doses for
the purpose of direct comparison. 18R-HEPE also carried
some activity in vivo (,5,12,18R-triHEPE), whereas it
was far less effective with isolated human PMNs in transen-
dothelial migration and apparently did not interact with re-
combinant LTB4 receptors at these concentrations.
Other widely used NSAIDs (i.e., acetaminophen and in-
domethacin) were also tested with recombinant COX-2
and C20:5 as in Table I to determine whether they altered
conversion to HEPE. Each inhibited 11-HEPE by .95%.
Interestingly, 18R-HEPE and 15R-HEPE formation per-
sisted (z1:1 ratio) in the presence of either acetaminophen
or indomethacin at concentrations as high as 2 mM, even
though the levels of 15R- and 18R-HEPE were reduced
by three to eight times their levels in the absence of inhibi-
tors (n 5 3). These findings indicate that the oxygenation
of v-3 fatty acids to R-containing monohydro(peroxy)-
containing products is not restricted to ASA treatment and
arachidonate. Hence, these commonly used NSAIDs and
selective COX-2 inhibitors (Table I) may still permit
PUFA oxygenation by activated ECs exposed to NSAIDs
(Fig. 2) and at sites of inflammation where the degree of
COX-2 interactions with drugs may be “leaky,” permitting
novel oxygenation of PUFAs.
Despite the many reports of v-3 PUFAs (i.e., C20:5)
possible beneficial impact in humans (1–6), oxygenation by
COX-2 to generate novel bioactive compounds has not
been addressed in humans or isolated cells. In fish, both
C20:5 and C20:4 are mobilized in macrophages and plate-
lets to produce 5- and 4-series eicosanoids, including PG,
LT, and LX, with essentially equal abundance (26). Our re-
sults indicate that inflammatory exudates from mice treated
with ASA and EPA generate novel compounds (Fig. 1) that
are also produced by human ECs, recombinant COX-2,
and PMNs (Fig. 2). Given the milligram to gram amounts
of v-3 PUFA taken as dietary supplements (1–6) and the
large area of microvasculature that can carry upregulated
COX-2, the conversion of EPA by ECs and neighboring
cells as observed in our experiments (Figs. 1–4) may repre-
sent a significant amount at local microenvironments.
These COX-2–NSAID-dependent conversions of v-3
PUFA are likely to be elevated within inflamed or diseased
tissues where COX-2 is upregulated and a determinant that
impacts fatty acid metabolism (14) when NSAIDs might be
of therapeutic benefit, namely with microinflammation.
Analogous to 15-epi-LX biosynthesis, EPA COX-2–
derived 15R-HEPE was converted by 5-lipoxygenation
with 5(6)-epoxide formation in leukocytes to give the 15-
epi-LX5 series (Fig. 4). The stable analogues of 15-epi-
LXA4, modified at their C15 position through position 20
with bulky groups, resist inactivating enzymes and are
more potent in vivo, inhibiting PMN traffic as well as for-
mation and actions of key proinflammatory cytokines (10,
16). Hence, 5-series 15-epi-LXs should act in a similar
fashion, as they possess a D17–18 double bond and thus
could function as an v-3–derived 15-epi-LX analogue.
Because COX-2–NSAID-dependent oxygenation (e.g.,
18R and15R) led to bioactive compounds in vivo that
block PMN transendothelial migration and infiltration, our
findings provide a basis for a novel mechanism of action of
NSAIDs and dietary v-3 supplementation, namely the gen-
eration of endogenous functional arrays of lipid signals (Ta-
ble I and Figs. 1 and 2) that could, by dampening key
events in microinflammation, mediate some of the benefi-
cial actions noted for v-3 therapies in human trials (1–6). In
this context, 13-HODE, a recognized lipoxygenase product
that downregulates platelet–EC interactions (29), is also
generated by COX-2 (Table I) and joins this pathway array
and class of mediators. As inappropriate inflammatory re-
sponses are now recognized as contributors to cardiovascu-
lar disease (30) as well as in clinical syndromes where PMN-
mediated tissue injury is important (11), our identification
of these novel v-3 PUFA processing pathways evoked by
cell–cell interactions and the unexpected impact of NSAIDs
opens new avenues for considering the potential clinical
protection provided by v-3 PUFA–based supplementation
(as from reference 6) and mechanisms to generate potent lo-
cal endogenous mediators that control microinflammation
(Figs. 3 and 4). Moreover, our findings offer a basis to cir-
cumvent unwanted effects of current antiinflammatory
therapies as well as potential biochemical indices and/or
markers of effective dietary v-3 supplementation.
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